title: [Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man].
abstract: The pharmacokinetics of pipecuronium bromide was studied in 9 male patients (ASA class 1-2, 20-65 years of age). Following a single intravenous dose of pipecuronium 0.08 mg.kg-1, plasma levels were measured by capillary gas chromatography. Plasma concentration-time curves were evaluated by fitting the data to a bi-exponential equation. The pharmacokinetic parameters of pipecuronium were compared with those of pancuronium (0.08 mg.kg-1) and vecuronium (0.08 mg.kg-1) previously obtained under the same anesthesia (66% N2O, 33% O2 and 1% halothane). With pipecuronium, following pharmacokinetic parameters were obtained; distribution half-life; T1/2 alpha = 3.9 +/- 0.7 min (mean +/- SEM), elimination half-life; T1/2 beta = 102 +/- 12 min, volume of the central compartment; V1 = 95 +/- 13 ml.kg-1, volume of distribution at steady state; Vdss = 264 +/- 41 ml.kg-1, clearance; Cl = 1.8 +/- 0.2 ml.min-1.kg-1. Microconstants of two-compartment open models (k12, k21, k10) were also calculated. Using Mann-Whitney's U-test, these parameters of pipecuronium were compared with those of pancuronium (n = 3) and vecuronium (n = 4). V1 and Vdss of pipecuronium were significantly larger than those of pancuronium (V1; 38 +/- 12 ml.kg-1 and Vdss; 120 +/- 4 ml.kg-1) (both P less than 0.10). Reflecting the larger central volume of pipecuronium, pipecuronium tended to have a larger clearance than that of pancuroniumu (Cl; 1.1 +/- 0.2 ml.min-1.kg-1).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Anesthesiology, Faculty of Medicine, University of Tokyo.
authors.forename: C
authors.initials: C
authors.lastname: Yajima
authors.forename: N
authors.initials: N
authors.lastname: Sugai
authors.forename: K
authors.initials: K
authors.lastname: Hanaoka
authors.forename: K
authors.initials: K
authors.lastname: Numata
authors.forename: K
authors.initials: K
authors.lastname: Yamamoto
authors.forename: Y
authors.initials: Y
authors.lastname: Kushida
authors.forename: S
authors.initials: S
authors.lastname: Murakami
authors.forename: H
authors.initials: H
authors.lastname: Yamamura
mesh_terms: D000328:Adult; D015113:Androstane-3,17-diol / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D000769:Anesthesia, Inhalation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009466:Neuromuscular Blocking Agents / Q000493:pharmacokinetics*; D010197:Pancuronium / Q000493:pharmacokinetics*; D017300:Pipecuronium; D010879:Piperazines / Q000493:pharmacokinetics*; D014673:Vecuronium Bromide / Q000493:pharmacokinetics*
chemical_list: D009466:Neuromuscular Blocking Agents; D010879:Piperazines; D017300:Pipecuronium; D015113:Androstane-3,17-diol; D014673:Vecuronium Bromide; D010197:Pancuronium